脂质奈米颗粒市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年，全球脂质奈米颗粒市场价值达10亿美元，预计到2034年将以13.3%的复合年增长率成长，达到35亿美元，这得益于对基于mRNA的疗法（尤其是在疫苗和基因药物领域）日益增长的需求。脂质奈米颗粒在mRNA递送中的应用已引起广泛关注，因为它们能够保护脆弱的mRNA分子，促进其安全且有效率地运输到细胞内。 mRNA疫苗领域的成功激发了对脂质奈米颗粒技术的更多投资和研究，使其应用范围从传染病扩展到癌症免疫疗法、蛋白质替代疗法和罕见遗传疾病治疗等领域。

随着生物技术和製药公司开发新一代基于mRNA的疗法，对LNP等优化递送系统的需求预计将激增。脂质组成、可扩展性和製造流程的进步提高了LNP在临床应用中的可用性，进一步推动了市场扩张。 LNP是药物递送的关键组成部分，能够包裹核酸、蛋白质和小分子等治疗剂，因此对广泛的医疗应用至关重要。

2024年，脂质体领域占据市场领先地位，价值达4.966亿美元。脂质体由脂质双层膜组成，是高效的药物传递系统，在药物稳定性和生物利用度方面具有优势。脂质体的多功能性，尤其是在肿瘤治疗领域，使其日益普及。此外，奈米技术的进步正在改进脂质体製剂，提高其载药效率和控释特性，从而进一步提升其市场份额。

2024年，治疗领域占据市场主导地位，市占率达65.1%，并以13%的稳定速度成长。 LNP有助于递送核酸类药物，例如mRNA、siRNA和DNA，从而治疗各种疾病。 LNP能够增强药物稳定性和精准递送，尤其是在癌症、传染病和遗传性疾病领域，这使得它们成为下一代药物开发的首选平台。随着越来越多的全球审批和临床试验的开展，治疗领域预计将保持其主导地位。

美国脂质奈米颗粒市场规模从2023年的3.342亿美元成长至2024年的3.806亿美元，预计2034年将以12.7%的复合年增长率成长。由于其强劲的生物技术和製药产业、大量的研发投入以及良好的监管环境，美国在该市场保持强大的领导地位。随着创新的持续和合作的扩大，美国很可能将继续引领市场。

全球脂质奈米颗粒产业的知名企业包括开曼化学公司 (Cayman Chemicals)、Arcturus Therapeutics、Alnylam Pharmaceuticals、Moderna、BioNTech SE、Sigma-Tau Pharmaceuticals、赢创 (Evonik)、默克 (Merck)、Ascendia Pharmaceuticals、ABP Biouret、Merck)、Ascendia Pharmaceuticals (ThermoFischer Scientific) 和 Acuitas Therapeutics。全球脂质奈米颗粒市场的企业为巩固其市场地位，采取的关键策略包括增加研发投入以增强脂质奈米颗粒 (LNP) 输送系统、探索基因疗法和癌症免疫疗法的新应用，以及建立策略合作伙伴关係以扩展其产品供应。此外，各企业也致力于改进製造工艺，以确保可扩展性和成本效益，从而满足市场对基于脂质奈米颗粒 (LNP) 的疗法日益增长的需求。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 慢性病盛行率上升
    • 对改善稳定性和生物利用度药物製剂的需求不断增长
    • 扩大研究经费和活动
    • mRNA 疗法的不断扩展
  • 产业陷阱与挑战
    • 严格的监管要求
    • 原料成本高
• 成长潜力分析
• 管道分析
• 监管格局
• 川普政府关税
  • 对贸易的影响
    • 贸易量中断
    • 报復措施
  • 对产业的影响
    • 供给侧影响（原料）
      • 主要材料价格波动
      • 供应链重组
      • 生产成本影响
    • 需求面影响（售价）
      • 价格传导至终端市场
      • 市占率动态
      • 消费者反应模式
  • 受影响的主要公司
  • 策略产业反应
    • 供应链重组
    • 定价和产品策略
    • 政策参与
  • 展望与未来考虑
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：依产品类型，2021 年至 2034 年

• 主要趋势
• 脂质体
• 固体脂质奈米颗粒
• 奈米结构脂质载体
• 其他产品类型

第六章：市场估计与预测：按应用，2021 年至 2034 年

• 主要趋势
• 疗法
  • 癌症
  • 真菌病
  • 止痛药
  • 疫苗
  • 其他应用
• 研究

第七章：市场估计与预测：依管理路线，2021 年至 2034 年

• 主要趋势
• 口服
• 肠外
• 外用
• 其他给药途径

第八章：市场估计与预测：依最终用途，2021 年至 2034 年

• 主要趋势
• 製药和生物技术公司
• 研究机构
• 其他最终用途

第九章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• ABP Biosciences
• Acuitas Therapeutics
• Alnylam Pharmaceuticals
• Arcturus Therapeutics
• Ascendia Pharmaceuticals
• Bayer
• BioNTech SE
• Cayman Chemicals
• Creative Biostructure
• Diant Pharma
• Evonik
• Merck
• Moderna
• Sigma-Tau Pharmaceuticals
• ThermoFischer Scientific

The Global Lipid Nanoparticles Market was valued at USD 1 billion in 2024, and it is estimated to grow at a CAGR of 13.3% to reach USD 3.5 billion by 2034, driven by the increasing demand for mRNA-based therapeutics, particularly in vaccines and genetic medicines. The use of lipid nanoparticles in the delivery of mRNA has gained significant attention due to their ability to protect fragile mRNA molecules, facilitating their safe and efficient transport into cells. This success in the mRNA vaccine space has sparked greater investment and research in LNP technologies, pushing their applications beyond infectious diseases into areas like cancer immunotherapy, protein replacement therapies, and treatments for rare genetic disorders.

The demand for optimized delivery systems like LNPs is expected to surge as biotech and pharmaceutical companies develop new generations of mRNA-based treatments. Advances in lipid composition, scalability, and manufacturing processes have enhanced the availability of LNPs for clinical applications, further fueling market expansion. LNPs are a key component in drug delivery, encapsulating therapeutic agents such as nucleic acids, proteins, and small molecules, making them critical for a wide range of medical applications.

The liposomes segment led the market in 2024, with a value of USD 496.6 million. Liposomes, composed of lipid bilayers, are highly efficient in drug delivery systems, offering advantages in drug stability and bioavailability. Their versatility, especially in oncology treatments, has grown their popularity. In addition, advancements in nanotechnology are improving liposomal formulations, increasing their drug loading efficiency and controlled release profiles, further boosting their market share.

The therapeutics segment dominated the market with a 65.1% share in 2024, growing at a steady rate of 13%. LNPs help deliver nucleic acid-based drugs such as mRNA, siRNA, and DNA to treat various diseases. Their ability to enhance drug stability and precision delivery, particularly in cancer, infectious diseases, and genetic disorders, has made them a preferred platform in next-generation drug development. With more global approvals and clinical trials underway, the therapeutics segment is expected to maintain its dominance.

United States Lipid Nanoparticles Market reached USD 380.6 million in 2024, growing from USD 334.2 million in 2023, and is expected to grow at a CAGR of 12.7% through 2034. The U.S. maintains a strong leadership position in the market, supported by its robust biotechnology and pharmaceutical industries, substantial R&D investments, and favorable regulatory environment. As innovations continue and collaborations expand, the U.S. will likely continue to lead the market.

Prominent players in the Global Lipid Nanoparticles Industry include Cayman Chemicals, Arcturus Therapeutics, Alnylam Pharmaceuticals, Moderna, BioNTech SE, Sigma-Tau Pharmaceuticals, Evonik, Merck, Ascendia Pharmaceuticals, ABP Biosciences, Creative Biostructure, Diant Pharma, Bayer, ThermoFischer Scientific, and Acuitas Therapeutics. Key strategies adopted by companies in the Global Lipid Nanoparticles Market to strengthen their position include increasing R&D investments to enhance LNP delivery systems, exploring new applications in gene therapies and cancer immunotherapies, and forming strategic partnerships to expand their product offerings. Additionally, companies are focused on improving manufacturing processes to ensure scalability and cost-effectiveness, enabling them to meet the growing demand for LNP-based therapeutics.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of chronic disease
    • 3.2.1.2 Growing demand for improved stability and bioavailability drug formulations
    • 3.2.1.3 Expanding research fundings and activities
    • 3.2.1.4 Growing expansion in mRNA therapeutics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory requirements
    • 3.2.2.2 High cost of raw materials
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Trump administration tariffs
  • 3.6.1 Impact on trade
    • 3.6.1.1 Trade volume disruptions
    • 3.6.1.2 Retaliatory measures
  • 3.6.2 Impact on the Industry
    • 3.6.2.1 Supply-side impact (raw materials)
      • 3.6.2.1.1 Price volatility in key materials
      • 3.6.2.1.2 Supply chain restructuring
      • 3.6.2.1.3 Production cost implications
    • 3.6.2.2 Demand-side impact (selling price)
      • 3.6.2.2.1 Price transmission to end markets
      • 3.6.2.2.2 Market share dynamics
      • 3.6.2.2.3 Consumer response patterns
  • 3.6.3 Key companies impacted
  • 3.6.4 Strategic industry responses
    • 3.6.4.1 Supply chain reconfiguration
    • 3.6.4.2 Pricing and product strategies
    • 3.6.4.3 Policy engagement
  • 3.6.5 Outlook and future considerations
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Liposomes
• 5.3 Solid lipid nanoparticles
• 5.4 Nanostructured lipid carriers
• 5.5 Other product types

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Therapeutics
  • 6.2.1 Cancer
  • 6.2.2 Fungal disease
  • 6.2.3 Analgesics
  • 6.2.4 Vaccines
  • 6.2.5 Other applications
• 6.3 Research

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Parenteral
• 7.4 Topical
• 7.5 Other routes of administration

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Pharmaceutical and biotechnology companies
• 8.3 Research Institutes
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 ABP Biosciences
• 10.2 Acuitas Therapeutics
• 10.3 Alnylam Pharmaceuticals
• 10.4 Arcturus Therapeutics
• 10.5 Ascendia Pharmaceuticals
• 10.6 Bayer
• 10.7 BioNTech SE
• 10.8 Cayman Chemicals
• 10.9 Creative Biostructure
• 10.10 Diant Pharma
• 10.11 Evonik
• 10.12 Merck
• 10.13 Moderna
• 10.14 Sigma-Tau Pharmaceuticals
• 10.15 ThermoFischer Scientific